Multi-omic Profiling Reveals Early Immunological Indicators for Identifying COVID-19 Progressors.


Journal

bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187

Informations de publication

Date de publication:
26 May 2023
Historique:
pubmed: 9 6 2023
medline: 9 6 2023
entrez: 9 6 2023
Statut: epublish

Résumé

The pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a rapid response by the scientific community to further understand and combat its associated pathologic etiology. A focal point has been on the immune responses mounted during the acute and post-acute phases of infection, but the immediate post-diagnosis phase remains relatively understudied. We sought to better understand the immediate post-diagnosis phase by collecting blood from study participants soon after a positive test and identifying molecular associations with longitudinal disease outcomes. Multi-omic analyses identified differences in immune cell composition, cytokine levels, and cell subset-specific transcriptomic and epigenomic signatures between individuals on a more serious disease trajectory (Progressors) as compared to those on a milder course (Non-progressors). Higher levels of multiple cytokines were observed in Progressors, with IL-6 showing the largest difference. Blood monocyte cell subsets were also skewed, showing a comparative decrease in non-classical CD14

Identifiants

pubmed: 37292797
doi: 10.1101/2023.05.25.542297
pmc: PMC10246026
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NHLBI NIH HHS
ID : OT2 HL158287
Pays : United States
Organisme : NHLBI NIH HHS
ID : UH3 HL140144
Pays : United States
Organisme : NHLBI NIH HHS
ID : R25 HL126140
Pays : United States
Organisme : NIH HHS
ID : C06 OD028307
Pays : United States
Organisme : NICHD NIH HHS
ID : R21 HD109777
Pays : United States
Organisme : NHLBI NIH HHS
ID : OT2 HL161847
Pays : United States
Organisme : NHLBI NIH HHS
ID : UG3 HL140144
Pays : United States
Organisme : NHLBI NIH HHS
ID : R56 HL138377
Pays : United States
Organisme : NHLBI NIH HHS
ID : R33 HL151254
Pays : United States

Investigateurs

Chen Chen (C)
Sairam Parthasarathy (S)
Victor F Tapson (VF)
James N Moy (JN)
Christopher R deFilippi (CR)
Ivan O Rosas (IO)
Mujeeb Basit (M)
Mirella Salvatore (M)
Jerry A Krishnan (JA)

Commentaires et corrections

Type : UpdateIn

Références

Nat Commun. 2021 Jul 5;12(1):4117
pubmed: 34226537
Lancet Infect Dis. 2020 Jun;20(6):656-657
pubmed: 32199493
mSystems. 2021 Oct 26;6(5):e0082921
pubmed: 34519528
Science. 2020 Sep 4;369(6508):1210-1220
pubmed: 32788292
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
Lancet Rheumatol. 2020 Dec;2(12):e754-e763
pubmed: 33015645
J Infect Dis. 2020 May 11;221(11):1762-1769
pubmed: 32227123
Front Cell Dev Biol. 2021 Jun 24;9:665519
pubmed: 34249918
J Immunol. 1989 May 15;142(10):3592-8
pubmed: 2785558
Front Immunol. 2013 Oct 22;4:339
pubmed: 24155746
J Immunol. 2018 Mar 1;200(5):1876-1888
pubmed: 29352005
Nat Commun. 2019 Jan 25;10(1):449
pubmed: 30683863
Cell Mol Immunol. 2021 Oct;18(10):2325-2333
pubmed: 34413488
Nature. 2023 Jan;613(7942):130-137
pubmed: 36517599
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet Respir Med. 2021 Dec;9(12):1365-1376
pubmed: 34672949
Front Immunol. 2020 Sep 23;11:560381
pubmed: 33072099
Life (Basel). 2022 Jan 29;12(2):
pubmed: 35207494
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
Nat Methods. 2016 Nov;13(11):919-922
pubmed: 27643841
Cold Spring Harb Perspect Biol. 2019 Oct 1;11(10):
pubmed: 30181377
JAMA Netw Open. 2022 Feb 01;5(2):e220527
pubmed: 35226079
EBioMedicine. 2023 Mar;89:104472
pubmed: 36801619
J Immunol. 2017 Sep 15;199(6):2008-2019
pubmed: 28768723
Nat Rev Immunol. 2022 Oct;22(10):639-649
pubmed: 35931818
Neurology. 2022 Aug 30;99(9):e916-e924
pubmed: 35654592
Nat Rev Immunol. 2020 Sep;20(9):529-536
pubmed: 32728222
Sci Transl Med. 2021 Jun 16;13(598):
pubmed: 34103408
Front Immunol. 2021 Jun 23;12:691725
pubmed: 34248984
Clin Immunol. 2021 May;226:108726
pubmed: 33845193
Nat Med. 2021 Oct;27(10):1752-1760
pubmed: 34480127
Comput Math Methods Med. 2022 Mar 19;2022:5650024
pubmed: 35345523
J Intern Med. 2020 Aug;288(2):192-206
pubmed: 32348588
Cell. 2019 Feb 7;176(4):897-912.e20
pubmed: 30686579
Front Immunol. 2019 Feb 12;10:169
pubmed: 30814995
Immunity. 2017 Dec 19;47(6):1129-1141.e5
pubmed: 29246443
Arterioscler Thromb Vasc Biol. 2020 Dec;40(12):2837-2844
pubmed: 33028093
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Nat Commun. 2020 Jul 8;11(1):3410
pubmed: 32641700
PLoS Comput Biol. 2017 Nov 3;13(11):e1005752
pubmed: 29099853
Immunity. 2021 Jun 8;54(6):1257-1275.e8
pubmed: 34051148
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Cells. 2022 Mar 01;11(5):
pubmed: 35269470
Sci Rep. 2021 Jun 9;11(1):12174
pubmed: 34108608
J Thromb Haemost. 2022 Apr;20(4):929-935
pubmed: 34970867
Genome Biol. 2014 Feb 03;15(2):R29
pubmed: 24485249
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nat Med. 2020 Oct;26(10):1623-1635
pubmed: 32807934
Cell. 2020 Dec 10;183(6):1479-1495.e20
pubmed: 33171100
Source Code Biol Med. 2008 Dec 16;3:17
pubmed: 19087314
Stroke. 2016 Mar;47(3):652-8
pubmed: 26846866
Cell Mol Immunol. 2020 May;17(5):533-535
pubmed: 32203188
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
Immunol Res. 2022 Dec;70(6):817-828
pubmed: 36222965
Am J Pathol. 2021 Jan;191(1):4-17
pubmed: 32919977
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
J Immunol. 1992 Aug 15;149(4):1326-33
pubmed: 1500720
Sci Immunol. 2020 Jul 15;5(49):
pubmed: 32669287
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
Cell. 2021 Dec 22;184(26):6243-6261.e27
pubmed: 34914922
Genome Biol. 2022 Jun 7;23(1):127
pubmed: 35672799
J Virol. 2003 Apr;77(7):4004-14
pubmed: 12634360
Am J Emerg Med. 2022 Jun;56:158-170
pubmed: 35397357
Trends Immunol. 2021 Jan;42(1):18-30
pubmed: 33277181
J Med Virol. 2021 Mar;93(3):1449-1458
pubmed: 32790106
J Clin Invest. 2019 Dec 2;129(12):5600-5614
pubmed: 31710310
Sci Transl Med. 2022 Jan 19;14(628):eabj7521
pubmed: 34698500
Nat Immunol. 2011 May 29;12(7):663-71
pubmed: 21623380
PLoS One. 2020 Nov 17;15(11):e0241955
pubmed: 33201896
EBioMedicine. 2021 Jul;69:103439
pubmed: 34157486
Mediators Inflamm. 2017;2017:1248201
pubmed: 28316371
J Immunol. 1995 Jan 15;154(2):620-32
pubmed: 7529281
J Cell Mol Med. 2022 Mar;26(5):1445-1455
pubmed: 35064759
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
Am J Respir Crit Care Med. 2013 Jun 15;187(12):1324-34
pubmed: 23611140
Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):E2807-16
pubmed: 24958888

Auteurs

Katherine A Drake (KA)

Verily Life Sciences, South San Francisco, CA.

Dimitri Talantov (D)

Janssen Research & Development, LLC, San Diego, CA.

Gary J Tong (GJ)

Verily Life Sciences, South San Francisco, CA.

Jack T Lin (JT)

Verily Life Sciences, South San Francisco, CA.

Simon Verheijden (S)

Janssen Research & Development, LLC, San Diego, CA.

Samuel Katz (S)

Verily Life Sciences, South San Francisco, CA.

Jacqueline M Leung (JM)

Verily Life Sciences, South San Francisco, CA.

Benjamin Yuen (B)

Verily Life Sciences, South San Francisco, CA.

Vinod Krishna (V)

Janssen Research & Development, LLC, San Diego, CA.

Michelle J Wu (MJ)

Verily Life Sciences, South San Francisco, CA.

Alex Sutherland (A)

Verily Life Sciences, South San Francisco, CA.

Sarah A Short (SA)

Verily Life Sciences, South San Francisco, CA.

Pouya Kheradpour (P)

Verily Life Sciences, South San Francisco, CA.

Maxwell Mumbach (M)

Verily Life Sciences, South San Francisco, CA.

Kate Franz (K)

Verily Life Sciences, South San Francisco, CA.

Vladimir Trifonov (V)

Janssen Research & Development, LLC, San Diego, CA.

Molly V Lucas (MV)

Janssen Research & Development, LLC, San Diego, CA.

James Merson (J)

Janssen Research & Development, LLC, San Diego, CA.

Charles C Kim (CC)

Verily Life Sciences, South San Francisco, CA.

Classifications MeSH